A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
To examine a new medication called regorafenib when used in those with hepatocellular carcinoma (HCC) who have failed previous treatment with sorafenib.
Hepatocellular Carcinoma (HCC)
Males and Females, aged 18 and older, with HCC, who have taken and failed treatment with sorafenib in the past.
18 - 99
Healthy Volunteers Needed
Duration of Participation
The study consists of "cycles." These cycles are 4 weeks long - or 28 days. There are several cycles in this study. Subjects will continue to complete these cycles indefinitely until their cancer gets worse or the study ends for another reason.
Kathy Bacon - 503-418-8332
Bayer Healthcare Pharmaceuticals, Inc
Subjects will be compensated $60 for each study visit completed. If a subject should leave the study early they will only receive compensation for the visits completed in full.